Smith+Nephew (NYSE: SNN) trims 2026 growth to 4% but keeps profit goals
Smith+Nephew has revised its full-year 2026 underlying revenue growth forecast down to around 4% from an earlier estimate of 6%, attributed to softer-than-expected first-half growth and pressures in US Orthopaedics and Advanced Wound Bioactives. Despite this reduction in revenue outlook, the company maintains its …